Replies to post #50254 on NorthWest Biotherapeutics Inc (NWBO)

[beachlifeisfun]

What you are missing is the enrollment ramp and ratio of placebo:treatment within that ramp. That is the obvious key to the whole story and that is why it is so guarded by NWBO. Though I do not think that NWBO has the placebo:treatment ramp ratio. However, if you consider the premise that each site will be required to have at least one placebo patient and consider the inception date of all of the sites...then that does provide at least some information. It is not a fact that every site must have at least one placebo patient...but it makes sense from a statistical and scientific perspective. Different hospitals/physicians/surgeons have different track records with regard to PFS and OS of their GBM patients...

[dpinvest]

The problem with analyzing her comment is that like everyone she is (or should be) blinded, so that using the term "everyone" about the trial is misguided. Like anybody else, all she should know is that the 240ish number of events milestone may not been reached (by October when the presentation was made), and without knowing more details one can only speculate that the SOC-only group may be doing well. That may be the case "as a group" but there may be not be much statistical significance within that data.

I guess all I am saying is that this is yet another intriguing NWBO clue that leaves bulls and bears clueless.